How does Imfinzi 500mg Injection work?

Imfinzi 500mg Injection is an immunotherapy that works by helping your immune system to fight cancer. This medicine blocks the action of PD-L1, exerts its anticancer effects by increasing T-cell activation, and allows them to destroy cancer cells.

How should I take Imfinzi 500mg Injection medicine?

This medicine is administered by a doctor or a nurse. It is injected slowly into your vein. This infusion usually lasts 60 minutes, and this medicine is given once every 2 to 4 weeks.

What are th side effects of Imfinzi 500mg Injection?

Side effects include cough, upper respiratory tract infections, fatigue, rash, hair loss, diarrhea, itching, abdominal pain, musculoskeletal or muscle pain, hoarse voice, night sweats, shortness of breath, pneumonitis, pneumonia, general infections with fever or chills, fungal infections in the mouth, tooth and mouth tissue infections, flu-like illness, abnormal liver and kidney test results, painful urination, swelling of the legs, overactive thyroid, and infusion reactions such as fever or flushing.

Can I drive after taking Imfinzi 500mg Injection medicine?

This medicine may cause dizziness, which affects your ability to drive and concentrate.

Deal of the Day — limited-time pharmacy picks!Deal of the Day — today's spotlight pharmacy prices, refreshed daily.

Imfinzi 500mg Injection

Name: Imfinzi 500mg Injection
Brand: imfinzi
Price: 154996.82 INR
Availability: InStock
Rating: 4.86 (7 reviews)

Rx Required

Salt Composition: Durvalumab

Expiry Date: 01/2028

Buy at $2,015.58

$2,015.58

Inclusive of all taxes

▼

1 vial

About The Product

Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Biliary Tract Cancer (BTC)
Hepatocellular Carcinoma (HCC)
Endometrial Cancer

Imfinzi (durvalumab), 500 mg, belongs to the group of immunotherapy medications.
The mechanism of action includes inhibition of the PD-L1 protein that increases the efficacy of the immune response toward the tumor.
It is primarily prescribed for several advanced cancers.
In lung cancer, it is used for adults with unresectable Stage III non-small cell lung cancer (NSCLC) that has not progressed after chemoradiation, and in combination with Tremelimumab and chemotherapy for metastatic NSCLC. For extensive-stage small cell lung cancer (SCLC), it is given alongside etoposide and carboplatin or cisplatin.
In biliary tract cancers, including bile duct and gallbladder cancer, it is combined with gemcitabine and cisplatin. It also plays a role in treating advanced or unresectable hepatocellular carcinoma (liver cancer), often with bevacizumab, and is used with carboplatin and paclitaxel for mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer.
Moreover, Imfinzi may be used to treat selected instances of invasive bladder cancer.
It is injected intravenously, and treatment is carried out until the disease progresses or side effects occur.
While it is beneficial, it has risks that are associated with immune reactions on organs such as the lungs, liver, gastrointestinal system, kidneys, and endocrine glands.

Side Effects

Like most anticancer drugs, Imfinzi 500mg Injection may cause some adverse effects on the body during the treatment. These can vary from mild to severe depending on the dose and the patient’s health condition. Inform your doctor immediately if you experience any persistent or unusual side effects. Side effects include:

Cough
Upper respiratory tract infections
Fatigue / tiredness
Rash
Hair loss
Diarrhea
Itching
Abdominal pain
Musculoskeletal pain (bones, muscles, joints)
Muscle pain (myalgia)
Hoarse voice (dysphonia)
Night sweats
Shortness of breath / breathlessness
Pneumonitis (lung inflammation)
Pneumonia (serious lung infection)
General infections (chills, fever)
Fungal infection in the mouth
Tooth and mouth soft tissue infections
Flu-like illness
Abnormal liver tests (AST/ALT increased)
Abnormal kidney function tests (blood creatinine increased)
Painful urination
Swelling of the legs (peripheral edema)
Overactive thyroid (fast heart rate, weight loss)
Infusion reactions (fever, flushing)

Safety Advice

Alcohol

Whether or not alcohol consumption interacts with Imfinzi 500 mg injection is unknown. You should consult with your doctor for further information.

Pregnancy

Do not take Imfinzi 500mg Injection without consulting the doctor in case of pregnancy, as it is an unsafe medicine during this period.

Breast Feeding

Imfinzi 500mg Injection is unsafe to use during breastfeeding as it may cause toxicity to the baby.

Driving

mfinzi 500mg Injection may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.

Kidney

Talk to your physician about any kidney disorders prior to treatment initiation.

Liver

Inform your physician about any liver diseases prior to administering the Imfinzi 500 mg injection. Monitoring liver functions on a regular basis is advised.

FAQs

This medicine is used to treat various cancers, including non-small cell lung cancer, liver cancer, endometrial cancer, biliary tract cancer and small cell lung cancer.

References

Dewi, I. G. A. G. S., Putri, L. A. L. N., Silalahi, L. D., Widha, I. G. A., Dewi, P., Hapsari, M. D., ... & Warditiani, N. K. (2025). Systematic Literature Review on Sterile Injectable Dates of Use, Stability and Implications for Use. Svāsthya: Trends in General Medicine and Public Health, 2(1), e66-e66 - https://journal.megsci-ind.org/index.php/Svasthya/article/view/66
Paik, P. K., Luo, J., Ai, N., Kim, R., Ahn, L., Biswas, A., ... & Kris, M. G. (2022). Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications, 13(1), 6095 - https://www.nature.com/articles/s41467-022-33719-6
Al-Salama, Z. T. (2021). Durvalumab: a review in extensive-stage SCLC. Targeted Oncology, 16(6), 857-864 - https://pubmed.ncbi.nlm.nih.gov/34731446/
Almasi, J., Thiesen, J., & Krämer, I. (2023). Physicochemical stability of durvalumab (Imfinzi®) concentrate for solution in original vials after first opening. Pharmaceutical Technology in Hospital Pharmacy, 8(1), 20230008 - https://www.degruyterbrill.com/document/doi/10.1515/pthp-2023-0008/html
Day-Storms, J. (2023). IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC - https://www.ahdbonline.com/issues/2023/september-2023-vol-16-payers-guide/imjudo-tremelimumab-actl-in-combination-with-imfinzi-durvalumab-receives-fda-approval-for-hcc-and-nsclc
Rashid, M. A. (2023). New Indications & Dosage Forms for Existing Drugs Vol. 26 (1). Bangladesh Pharmaceutical Journal, 26(1), 114-118 - https://www.banglajol.info/index.php/BPJ/article/view/71454/47793

Last updated: 5 Aug 2026 | 04:32 PM (IST)

Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only

Not a substitute for professional medical advice

Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.

Read full medical disclaimer in Terms & Conditions